Publication|Articles|October 6, 2025
Supplements and Featured Publications
- The Role of TEVIMBRA® (tislelizumab-jsgr) in First-Line ESCC Treatment
The Role of TEVIMBRA® (tislelizumab-jsgr) in First-Line ESCC Treatment
Advertisement
This Clinical Brief was sponsored by BeOne Medicines.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
How Socioeconomic and Clinical Factors Influence Obesity Treatment
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5